FIELD: biotechnology.
SUBSTANCE: invention relates to an isolated antibody or its antigen-binding fragment, which specifically bind α vβ 8 integrin, the method of its preparation, as well as compositions and kits containing it. An isolated nucleic acid that encodes the amino acid sequences of an antibody or an antigen-binding fragment thereof, as well as a vector and a cell containing it, are also disclosed. The invention also relates to a method of reducing activity of α vβ 8 integrin in the subject, as well as the method of determination ofα vβ 8 integrin in a sample, tissue or cell containing the above antibody or a fragment thereof.
EFFECT: invention is effective for treatment or prevention of cancer or a condition mediated by the activity ofα vβ 8 integrin.
51 cl, 31 dwg, 19 tbl, 26 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES AGAINST CXCR5, THEIR COMPOSITIONS AND USE | 2018 |
|
RU2798422C2 |
| TYPES OF COMBINATION THERAPY USING CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS | 2017 |
|
RU2809160C2 |
| TRISPECIFIC AND/OR TRIVALENT BINDING PROTEINS USING CROSSOVER FORMAT WITH DOUBLE VARIABLE DOMAIN (CODV) FOR TREATING INFECTION CAUSED BY HIV | 2020 |
|
RU2820164C2 |
| ANTI-C5 ANTIBODIES AND THEIR USE | 2018 |
|
RU2774716C2 |
| DNA ANTIBODY CONSTRUCTIONS FOR USE AGAINST LYME DISEASE | 2017 |
|
RU2813829C2 |
| CHIMERIC ANTIGEN RECEPTORS FOR CANCER TREATMENT | 2017 |
|
RU2826270C2 |
| COMBINATIONS OF ANTIBODIES TO STAPHYLOCOCCUS AUREUS | 2019 |
|
RU2804815C2 |
| EGFL6-SPECIFIC MONOCLONAL ANTIBODIES AND THEIR APPLICATION METHODS | 2017 |
|
RU2779902C2 |
| MATERIALS AND METHODS USED FOR TREATMENT OF RESPIRATORY DISEASES IN DOGS | 2020 |
|
RU2811752C2 |
| ANTIBODIES AGAINST TISSUE FACTOR PATHWAY INHIBITOR AND THEIR USE | 2016 |
|
RU2815681C1 |
